open access

Vol 84, No 6 (2016)
Review paper
Published online: 2016-12-07
Submitted: 2016-05-20
Accepted: 2016-09-14
Get Citation

Pain management in lung cancer

Fariz Nurwidya, Elisna Syahruddin, Faisal Yunus
DOI: 10.5603/ARM.2016.0043
Pubmed: 28009033
Adv Respir Med 2016;84(6):331-336.

open access

Vol 84, No 6 (2016)
Published online: 2016-12-07
Submitted: 2016-05-20
Accepted: 2016-09-14


Lung cancer is the leading cause of cancer-related mortality worldwide. Not only burdened by the limited overall survival, lung cancer patient also suffer from various symptoms, such as pain, that implicated in the quality of life. Cancer pain is a complicated and transiently dynamic symptom that results from multiple mechanisms. This review will describe the pathophysiology of cancer pain and general approach in managing a patient with lung cancer pain. The use of opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and adjuvant analgesia, as part of the pharmacology therapy along with interventional strategy, will also be discussed.


Lung cancer is the leading cause of cancer-related mortality worldwide. Not only burdened by the limited overall survival, lung cancer patient also suffer from various symptoms, such as pain, that implicated in the quality of life. Cancer pain is a complicated and transiently dynamic symptom that results from multiple mechanisms. This review will describe the pathophysiology of cancer pain and general approach in managing a patient with lung cancer pain. The use of opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and adjuvant analgesia, as part of the pharmacology therapy along with interventional strategy, will also be discussed.

Get Citation


pain, lung cancer, therapeutic strategy

Supp./Additional Files (1)
Title page
About this article

Pain management in lung cancer


Advances in Respiratory Medicine


Vol 84, No 6 (2016)

Article type

Review paper



Published online






Bibliographic record

Adv Respir Med 2016;84(6):331-336.


lung cancer
therapeutic strategy


Fariz Nurwidya
Elisna Syahruddin
Faisal Yunus

References (95)
  1. Kurita GP, Sjøgren P. Pain management in cancer survivorship. Acta Oncol. 2015; 54(5): 629–634.
  2. van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007; 18(9): 1437–1449.
  3. Wu J, Wei Y, Shi J, et al. The potential therapeutic targets to bone pain induced by cancer metastasis. J Cancer Res Ther. 2013; 9 Suppl: S135–S141.
  4. Walter FM, Rubin G, Bankhead C, et al. Symptoms and other factors associated with time to diagnosis and stage of lung cancer: a prospective cohort study. Br J Cancer. 2015; 112 Suppl 1: S6–13.
  5. Zylla D, Kuskowski MA, Gupta K, et al. Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth. 2014 [Epub ahead of print].
  6. GF G. Scientific Issues of Pain and Distress. In National Research Council (US) Committee on Regulatory Issues in Animal Care and Use. Definition of Pain and Distress and Reporting Requirements for Laboratory Animals: Proceedings of the Workshop Held Washington, 22.06.2000.
  7. Carver AC, Foley KM. Types of pain. In: Kufe DW, Pollock RE, Weichselbaum RR. ed. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker, Hamilton 2003.
  8. Davis MP. Drug management of visceral pain: concepts from basic research. Pain Res Treat. 2012: 265605.
  9. Jensen TS, Baron R, Haanpaa M, et al. A new definition of neuropathic pain. Pain. 2011; 152: 2204–2205.
  10. Boland EG, Mulvey MR, Bennett MI. Classification of neuropathic pain in cancer patients. Curr Opin Support Palliat Care. 2015; 9(2): 112–115.
  11. Messina J, Darwish M, Fine PG. Fentanyl buccal tablet. Drugs Today (Barc) . 2008; 44: 41–54.
  12. Gatti A, Gentili M, Iorno V, et al. Beyond the traditional definition of breakthrough pain: an observational study. Adv Ther. 2013; 30(3): 298–305.
  13. Mercadante S, Vitrano V. Pain in patients with lung cancer: pathophysiology and treatment. Lung Cancer. 2010; 68(1): 10–15.
  14. Bentley JN, Viswanathan A, Rosenberg WS, et al. Treatment of medically refractory cancer pain with a combination of intrathecal neuromodulation and neurosurgical ablation: case series and literature review. Pain Med. 2014; 15(9): 1488–1495.
  15. Gerner P. Postthoracotomy pain management problems. Anesthesiol Clin. 2008; 26(2): 355–367.
  16. Hopkins KG, Hoffman LA, Dabbs AD, et al. Postthoracotomy Pain Syndrome Following Surgery for Lung Cancer: Symptoms and Impact on Quality of Life. J Adv Pract Oncol. 2015; 6(2): 121–132.
  17. Ripamonti CI, Bandieri E, Roila F, et al. ESMO Guidelines Working Group. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2011; 22 Suppl 6: vi69–vi77.
  18. Martinez KA, Snyder CF, Malin JL, et al. Is race/ethnicity related to the presence or severity of pain in colorectal and lung cancer? J Pain Symptom Manage. 2014; 48(6): 1050–1059.
  19. Daniel M, Keefe FJ, Lyna P, et al. Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels. J Pain. 2009; 10(3): 323–328.
  20. Gonzalez A, Japuntich S, Keating NL, et al. Pain experiences among a population-based cohort of current, former, and never regular smokers with lung and colorectal cancer. Cancer. 2014; 120(22): 3554–3561.
  21. Prasertsri N, Holden J, Keefe FJ, et al. Repressive coping style: relationships with depression, pain, and pain coping strategies in lung cancer outpatients. Lung Cancer. 2011; 71(2): 235–240.
  22. Reyes-Gibby CC, Wang J, Spitz M, et al. Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients. J Pain Symptom Manage. 2013; 46(2): 161–172.
  23. Reyes-Gibby CC, Spitz M, Wu X, et al. Cytokine genes and pain severity in lung cancer: exploring the influence of TNF-alpha-308 G/A IL6-174G/C and IL8-251T/A. Cancer Epidemiol Biomarkers Prev. 2007; 16(12): 2745–2751.
  24. Ahmedzai SH, Barrie J, Bennet M. Cancer pain management. The British Pain Society, London 2010.
  25. Reyes-Gibby CC, Spitz MR, Yennurajalingam S, et al. Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2009; 18(10): 2636–2642.
  26. Schmidt BL, Ye Yi, Ono K, et al. The neurobiology of cancer pain. Neuroscientist. 2014; 20(5): 546–562.
  27. Potter J, Higginson IJ. Pain experienced by lung cancer patients: a review of prevalence, causes and pathophysiology. Lung Cancer. 2004; 43(3): 247–257.
  28. Reyes-Gibby CC, Swartz MD, Yu X, et al. Symptom clusters of pain, depressed mood, and fatigue in lung cancer: assessing the role of cytokine genes. Support Care Cancer. 2013; 21(11): 3117–3125.
  29. Schmidt BL, Hamamoto DT, Simone DA, et al. Mechanism of cancer pain. Mol Interv. 2010; 10(3): 164–178.
  30. Ye Yi, Dang D, Zhang J, et al. Nerve growth factor links oral cancer progression, pain, and cachexia. Mol Cancer Ther. 2011; 10(9): 1667–1676.
  31. Zhu Z, Friess H, diMola FF, et al. Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol. 1999; 17(8): 2419–2428.
  32. Heitsch H. Bradykinin B2 receptor as a potential therapeutic target. Drug News Perspect. 2000; 13(4): 213–225.
  33. Golias Ch, Charalabopoulos A, Stagikas D, et al. The kinin system--bradykinin: biological effects and clinical implications. Multiple role of the kinin system--bradykinin. Hippokratia. 2007; 11(3): 124–128.
  34. da Costa PLN, Sirois P, Tannock IF, et al. The role of kinin receptors in cancer and therapeutic opportunities. Cancer Lett. 2014; 345(1): 27–38.
  35. Tang Y, Peng H, Liao Q, et al. Study of breakthrough cancer pain in an animal model induced by endothelin-1. Neurosci Lett. 2016; 617: 108–115.
  36. Yan XB, Peng TC, Huang D. Correlations between plasma endothelin-1 levels and breakthrough pain in patients with cancer. Onco Targets Ther. 2015; 8: 3703–3706.
  37. Lam DK, Schmidt BL. Serine proteases and protease-activated receptor 2-dependent allodynia: a novel cancer pain pathway. Pain. 2010; 149(2): 263–272.
  38. Lam DK, Dang D, Zhang J, et al. Novel animal models of acute and chronic cancer pain: a pivotal role for PAR2. J Neurosci. 2012; 32(41): 14178–14183.
  39. Justus CR, Dong L, Yang LiV. Acidic tumor microenvironment and pH-sensing G protein-coupled receptors. Front Physiol. 2013; 4: 354.
  40. Yoneda T, Hata K, Nakanishi M, et al. Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain. Bone. 2011; 48(1): 100–105.
  41. Reyes-Gibby CC, El Osta B, Spitz MR, et al. The influence of tumor necrosis factor-alpha -308 G/A and IL-6 -174 G/C on pain and analgesia response in lung cancer patients receiving supportive care. Cancer Epidemiol Biomarkers Prev. 2008; 17(11): 3262–3267.
  42. Pembroke CA, Byrne A, Lester JF, et al. Persistent unilateral facial pain in lung cancer patients with mediastinal nodal involvement. Lung Cancer. 2013; 82(1): 173–175.
  43. Eisa N, Alhafez B, Alraiyes AH, et al. Abdominal pain as initial presentation of lung cancer. BMJ Case Rep. 2014.
  44. Schmidt BJ, Smith SL. Isolated splenic metastasis from primary lung adenocarcinoma. South Med J. 2004; 97(3): 298–300.
  45. Imai Y, Imai K, Kimura T, et al. Evaluation of postoperative pregabalin for attenuation of postoperative shoulder pain after thoracotomy in patients with lung cancer, a preliminary result. Gen Thorac Cardiovasc Surg. 2015; 63(2): 99–104.
  46. Jho HJ, Kim Y, Kong KAe, et al. Knowledge, practices, and perceived barriers regarding cancer pain management among physicians and nurses in Korea: a nationwide multicenter survey. PLoS One. 2014; 9(8): e105900.
  47. Canivet D, Delvaux N, Gibon AS, et al. Improving communication in cancer pain management nursing: a randomized controlled study assessing the efficacy of a communication skills training program. Support Care Cancer. 2014; 22(12): 3311–3320.
  48. Miller LM, Lyons KS, Bennett JA. Incongruent perceptions of pain and physical function among families living with lung cancer. Support Care Cancer. 2015; 23(9): 2755–2762.
  49. Ferrell B, Koczywas M, Grannis F, et al. Palliative care in lung cancer. Surg Clin North Am. 2011; 91: 403–417.
  50. Schug SA, Chandrasena C. Pain management of the cancer patient. Expert Opin Pharmacother. 2015; 16(1): 5–15.
  51. Prommer EE. Pharmacological Management of Cancer-Related Pain. Cancer Control. 2015; 22(4): 412–425.
  52. Brant JM. The global experience of cancer pain. Asian Pac J Cancer Prev. 2010; 11 Suppl 1: 7–12.
  53. Nabal M, Librada S, Redondo MJ, et al. The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliat Med. 2012; 26(4): 305–312.
  54. Sollami A, Marino L, Fontechiari S, et al. Strategies for pain management: a review. Acta Biomed. 2015; 86 Suppl 2: 150–157.
  55. Smith TJ, Saiki CB. Cancer Pain Management. Mayo Clin Proc. 2015; 90(10): 1428–1439.
  56. Leppert W, Łuczak J. The role of tramadol in cancer pain treatment--a review. Support Care Cancer. 2005; 13(1): 5–17.
  57. Plante GE, VanItallie TB. Opioids for cancer pain: the challenge of optimizing treatment. Metabolism. 2010; 59 Suppl 1: S47–S52.
  58. Przewłocki R, Przewłocka B. Opioids in chronic pain. Eur J Pharmacol. 2001; 429(1-3): 79–91.
  59. Mercadante S. The use of opioids for treatment of cancer pain. Expert Opin Pharmacother. 2015; 16(3): 389–394.
  60. Portenoy RK, Ahmed E. Principles of opioid use in cancer pain. J Clin Oncol. 2014; 32(16): 1662–1670.
  61. Vadalouca A, Moka E, Argyra E, et al. Opioid rotation in patients with cancer: a review of the current literature. J Opioid Manag. 2008; 4(4): 213–250.
  62. Cherny NJ, Chang V, Frager G, et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer. 1995; 76(7): 1283–1293.
  63. Huang Z, Liang L, Li L, et al. Opioid doses required for pain management in lung cancer patients with different cholesterol levels: negative correlation between opioid doses and cholesterol levels. Lipids Health Dis. 2016; 15: 47.
  64. Simpson DM, Messina J, Xie F, et al. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007; 29(4): 588–601.
  65. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs. 2003; 63(1): 17–32.
  66. Vallerand AH. The use of long-acting opioids in chronic pain management. Nurs Clin North Am. 2003; 38(3): 435–445.
  67. Romem A, Tom SE, Beauchene M, et al. Pain management at the end of life: A comparative study of cancer, dementia, and chronic obstructive pulmonary disease patients. Palliat Med. 2015; 29(5): 464–469.
  68. Leppert W. Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol Rep. 2009; 61(6): 978–992.
  69. Salminen EK, Silvoniemi M, Syrjänen K, et al. Opioids in pain management of mesothelioma and lung cancer patients. Acta Oncol. 2013; 52(1): 30–37.
  70. Lennon FE, Moss J, Singleton PA. The μ-opioid receptor in cancer progression: is there a direct effect? Anesthesiology. 2012; 116(4): 940–945.
  71. Singleton PA, Mirzapoiazova T, Hasina R, et al. Increased μ-opioid receptor expression in metastatic lung cancer. Br J Anaesth. 2014; 113 Suppl 1: i103–i108.
  72. Lennon FE, Mirzapoiazova T, Mambetsariev B, et al. The Mu opioid receptor promotes opioid and growth factor-induced proliferation, migration and Epithelial Mesenchymal Transition (EMT) in human lung cancer. PLoS One. 2014; 9(3): e91577.
  73. Cata JP, Keerty V, Keerty D, et al. A retrospective analysis of the effect of intraoperative opioid dose on cancer recurrence after non-small cell lung cancer resection. Cancer Med. 2014; 3(4): 900–908.
  74. Maher DP, Wong W, White PF, et al. Association of increased postoperative opioid administration with non-small-cell lung cancer recurrence: a retrospective analysis. Br J Anaesth. 2014; 113 Suppl 1: i88–i94.
  75. Minami S, Fujimoto K, Ogata Y, et al. Opioids have no negative effect on the survival time of patients with advanced lung cancer in an acute care hospital. Support Care Cancer. 2015; 23(8): 2245–2254.
  76. Gamborg H, Riis J, Christrup L, et al. Effect of intraoral and subcutaneous morphine on dyspnea at rest in terminal patients with primary lung cancer or lung metastases. J Opioid Manag. 2013; 9(4): 269–274.
  77. Vardy J, Agar M. Nonopioid drugs in the treatment of cancer pain. J Clin Oncol. 2014; 32(16): 1677–1690.
  78. Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist. 2004; 9(5): 571–591.
  79. Longson D, Bhojani I, Brandner B et al. Neuropathic pain — Pharmacological management. In The pharmacological management of neuropathic pain in adults in non-specialist settings. Manchester: National Institute for Health and Care Excellence 2013.
  80. Mercadante S, Villari P, Ferrera P. Dialogues on complex analgesic strategies for difficult pain syndromes. Support Care Cancer. 2004; 12(8): 599–603.
  81. Vayne-Bossert P, Afsharimani B, Good P, et al. Interventional options for the management of refractory cancer pain--what is the evidence? Support Care Cancer. 2016; 24(3): 1429–1438.
  82. Yennurajalingam S, Dev R, Walker PW, et al. Challenges associated with spinal opioid therapy for pain in patients with advanced cancer: a report of three cases. J Pain Symptom Manage. 2010; 39(5): 930–935.
  83. Chen J, Zhang Y, Huang C, et al. [Effects of thoracic paravertebral block on postoperative analgesia and serum level of tumor marker in lung cancer patients undergoing video-assisted thoracoscopic surgery]. Zhongguo Fei Ai Za Zhi. 2015; 18(2): 104–109.
  84. Peláez R, Pascual G, Aguilar JL, et al. Paravertebral cervical nerve block in a patient suffering from a Pancoast tumor. Pain Med. 2010; 11(12): 1799–1802.
  85. Kanpolat Y, Ugur HC, Ayten M, et al. Computed tomography-guided percutaneous cordotomy for intractable pain in malignancy. Neurosurgery. 2009; 64(3 Suppl): ons187–ons193.
  86. Oran NT. Percutaneous chordotomy for managing cancer pain. AORN J. 2001; 74(3): 363-369–371-362.
  87. Kanpolat Y, Ozdemir M, Al-Beyati E. CT-guided percutaneous cordotomy for intractable pain in what is more than a disease: lung malignancies. Turk Neurosurg. 2013; 23(1): 81–87.
  88. Kanpolat Y, Savas A, Ucar T, et al. CT-guided percutaneous selective cordotomy for treatment of intractable pain in patients with malignant pleural mesothelioma. Acta Neurochir (Wien). 2002; 144(6): 595–599.
  89. Bekar A, Kocaeli H, Abaş F, et al. Bilateral high-level percutaneous cervical cordotomy in cancer pain due to lung cancer: a case report. Surg Neurol. 2007; 67(5): 504–507.
  90. Kanpolat Y, Caglar S, Akyar S, et al. CT-guided pain procedures for intractable pain in malignancy. Acta Neurochir Suppl. 1995; 64: 88–91.
  91. Paley CA, Johnson MI, Tashani OA, et al. Acupuncture for cancer pain in adults. Cochrane Database Syst Rev. 2011; 1(1): CD007753–55.
  92. Brundage MD, Bezjak A, Dixon P, et al. The role of palliative thoracic radiotherapy in non-small cell lung cancer. Can J Oncol. 1996; 6 Suppl 1: 25–32.
  93. Rees GJ, Devrell CE, Barley VL, et al. Palliative radiotherapy for lung cancer: two versus five fractions. Clin Oncol (R Coll Radiol). 1997; 9(2): 90–95.
  94. Erridge SC, Gaze MN, Price A, et al. Symptom control and quality of life in people with lung cancer: a randomised trial of two palliative radiotherapy fractionation schedules. Clin Oncol (R Coll Radiol). 2005; 17(1): 61–67.
  95. Ishiyama H, Shibata A, Niino K, et al. Relationship between morphine and radiotherapy for management of symptomatic bone metastases from lung cancer. Support Care Cancer. 2004; 12(10): 743–745.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: